Intact Investment Management Inc. Makes New $650,000 Investment in DexCom, Inc. (NASDAQ:DXCM)

Intact Investment Management Inc. acquired a new position in DexCom, Inc. (NASDAQ:DXCM) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 9,700 shares of the medical device company’s stock, valued at approximately $650,000.

Other institutional investors have also added to or reduced their stakes in the company. Team Hewins LLC increased its position in shares of DexCom by 3.4% during the first quarter. Team Hewins LLC now owns 2,555 shares of the medical device company’s stock worth $354,000 after acquiring an additional 83 shares during the period. Bleakley Financial Group LLC increased its position in shares of DexCom by 1.3% during the first quarter. Bleakley Financial Group LLC now owns 6,856 shares of the medical device company’s stock worth $951,000 after acquiring an additional 87 shares during the period. Capital Insight Partners LLC increased its position in shares of DexCom by 2.5% during the second quarter. Capital Insight Partners LLC now owns 3,690 shares of the medical device company’s stock worth $418,000 after acquiring an additional 90 shares during the period. HM Payson & Co. increased its position in shares of DexCom by 6.0% during the first quarter. HM Payson & Co. now owns 1,780 shares of the medical device company’s stock worth $247,000 after acquiring an additional 100 shares during the period. Finally, Clear Creek Financial Management LLC increased its position in shares of DexCom by 4.2% during the second quarter. Clear Creek Financial Management LLC now owns 2,961 shares of the medical device company’s stock worth $336,000 after acquiring an additional 120 shares during the period. Institutional investors own 97.75% of the company’s stock.

Insider Transactions at DexCom

In other news, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now directly owns 264,915 shares in the company, valued at approximately $18,318,872.25. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the transaction, the chief operating officer now directly owns 264,915 shares in the company, valued at $18,318,872.25. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Sadie Stern sold 426 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the transaction, the executive vice president now owns 75,451 shares of the company’s stock, valued at $5,217,436.65. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.30% of the company’s stock.

DexCom Trading Down 0.9 %

NASDAQ:DXCM opened at $69.70 on Tuesday. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The firm has a fifty day simple moving average of $69.77 and a 200-day simple moving average of $94.92. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The company has a market capitalization of $27.22 billion, a P/E ratio of 41.74, a PEG ratio of 2.16 and a beta of 1.17.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Baird R W lowered shares of DexCom from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 26th. Morgan Stanley cut their price objective on shares of DexCom from $120.00 to $75.00 and set an “equal weight” rating on the stock in a report on Friday, July 26th. Wells Fargo & Company lifted their price objective on shares of DexCom from $80.00 to $90.00 and gave the company an “overweight” rating in a report on Friday, October 25th. Leerink Partners cut their price objective on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Finally, Royal Bank of Canada cut their price objective on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Seven investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $104.59.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.